Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 82
Filter
Add more filters

Uruguay Oncology Collection
Publication year range
1.
Gan To Kagaku Ryoho ; 46(13): 1990-1992, 2019 Dec.
Article in Japanese | MEDLINE | ID: mdl-32157036

ABSTRACT

A 74-year-old man with anemia visited our department. Esophagogastroduodenoscopy showed a type 2 lesion from the angulus to the antrum. Histopathological findings indicated gastric neuroendocrine carcinoma. Colonoscopy showed a type 1 lesion at the cecum. Distal gastrectomy was performed with D1+lymph node dissection, Roux-en-Y reconstruction, and ileocecal resection with D3 lymph node dissection. The patient was pathologically diagnosed with large-cell neuroendocrine carcinoma in the stomach, pT4a(SE), med, INF a>>b-c, ly1-2, v1(SM, EVG), pN0, pM0, pStageⅡB, and adenocarcinoma (tub1>tub2)of the cecum, pT2(MP), ly1(HE), v1(EVG, SM), pN0, pM0, pStageⅠ. Postoperatively, he received oral S-1 as an adjuvant chemotherapy. His postoperative course was uneventful without any recurrence over 18 months.


Subject(s)
Adenocarcinoma , Carcinoma, Neuroendocrine , Cecal Neoplasms/pathology , Neoplasms, Multiple Primary , Stomach Neoplasms , Adenocarcinoma/therapy , Aged , Antineoplastic Combined Chemotherapy Protocols , Carcinoma, Neuroendocrine/therapy , Cecal Neoplasms/therapy , Cecum , Gastrectomy , Humans , Male , Neoplasm Recurrence, Local , Stomach Neoplasms/therapy
2.
Gastrointest Endosc ; 87(2): 529-539, 2018 02.
Article in English | MEDLINE | ID: mdl-28882576

ABSTRACT

BACKGROUND AND AIMS: Colorectal mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease. The purpose of this study was to investigate the clinical and endoscopic features of colorectal MALT lymphoma. METHODS: Patients diagnosed with colorectal MALT lymphoma at Asan Medical Center from 2002 to 2016 were eligible. Medical records were reviewed to investigate clinical features and treatment outcomes. Endoscopic pictures were assessed to characterize the endoscopic features of colorectal MALT lymphoma. RESULTS: A total of 51 patients were enrolled. The median age was 60 years (interquartile range, 55-71), and 21 (41%) were men. Twenty-six patients (51%) were asymptomatic. Forty-four patients (86%) were in early disease stages, namely Lugano stages I, II, and IIE. Endoscopic appearances were classified as 4 distinct types: subepithelial tumor type (26 patients, 51%), polyposis type (10 patients, 20%), epithelial mass type (7 patients, 14%), and ileitis type (8 patients, 16%). The rectum (20 patients, 39%) was the most common location, followed by the ileocecal area (15 patients, 30%). An initial endoscopic impression of lymphoma was made in only 7 patients. Forceps biopsy sampling as the initial tissue acquisition method could histologically diagnose MALT lymphoma in 28 of 35 patients (80%). Polypectomy as the initial histologic diagnosis could diagnose MALT lymphoma in 16 of 16 patients. Progression-free and overall survival rates at 5 years were 92% and 94%, respectively. CONCLUSIONS: Colorectal MALT lymphomas show various endoscopic appearances, complicating the endoscopic suspicion of colorectal MALT lymphoma. The prognosis of colorectal MALT lymphoma was excellent.


Subject(s)
Cecal Neoplasms/diagnostic imaging , Cecal Neoplasms/pathology , Lymphoma, B-Cell, Marginal Zone/diagnostic imaging , Lymphoma, B-Cell, Marginal Zone/pathology , Rectal Neoplasms/diagnostic imaging , Rectal Neoplasms/pathology , Aged , Asymptomatic Diseases , Biopsy , Cecal Neoplasms/therapy , Colonoscopy , Disease-Free Survival , Female , Humans , Intestinal Mucosa/pathology , Lymphoma, B-Cell, Marginal Zone/surgery , Male , Middle Aged , Neoplasm Staging , Rectal Neoplasms/therapy , Survival Rate
3.
Gan To Kagaku Ryoho ; 44(12): 1698-1700, 2017 Nov.
Article in Japanese | MEDLINE | ID: mdl-29394747

ABSTRACT

In June 1997, the patient underwent an operation for cecal colon cancer pStage II .I n May 1999, a liver metastasis at S6 was detected and the patient received a partial liver resection.In April 2004, a liver metastasis in S4 was detected and another partial liver resection was performed.In November 2008, he complained of hemoptysis and cough.The chest CT examination showed lymph node metastases in the mediastinum that invaded the left main bronchus.We performed chemo-radiotherapy for local control from January 2009. Because the lymph nodes were reduced remarkably and clinical complaints disappeared, we administrated a mFOLFOX6 regimen from June.We recognized the effect of treatment to be a complete response.In February 2014, we detected a lymph nodes recurrence around a right pulmonary artery.We performed chemo-radiotherapy again because the patient declined surgery.However, lymph node metastases did not completely respond.We then performed chemotherapy 30 times using a FOLFIRI plus panitumumab regimen.On PET-CT, the recurrent lesion did not show a hot spot.We experienced a case that responded to chemo-radiotherapy for long-term control of lymph node recurrence.


Subject(s)
Cecal Neoplasms/therapy , Chemoradiotherapy , Mediastinum/pathology , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Humans , Lymphatic Metastasis , Male , Time Factors
4.
Int J Colorectal Dis ; 30(9): 1173-83, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26054387

ABSTRACT

PURPOSE: Stage III colon cancer is currently treated as an entity with a unified therapeutic principle. The aim of the retrospective study is to explore the clinicopathological characteristics and outcomes of site-specific stage III colon cancers and the influences of tumor location on prognosis. METHODS: Eight hundred ninety-five patients with stage III colon cancer treated with radical operation and subsequent adjuvant chemotherapy (5-fluorouracil/oxaliplatin) were divided into seven groups according to colon segment (cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, and sigmoid colon). Expression of excision repair cross-complementing group 1 (ERCC1) and thymidylate synthase (TS) was examined by immunohistochemistry. We assessed if differences exist in patient characteristics and clinic outcomes between the seven groups. RESULTS: There were significant differences in tumor differentiation (P < 0.001), T stage (P < 0.001), N stage (P < 0.001), American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) stage (P < 0.001), metachronous liver metastasis (P < 0.001), metachronous lung metastasis (P < 0.001), and ERCCI expression (P < 0.001) between the seven groups. Both 5-year recurrence-free survival (RFS) and 5-year overall survival (OS) exhibited significant differences (both P < 0.001) with survival gradually decreasing from cecum to sigmoid colon. Cox regression analyses identified that tumor location was an independent prognostic factor for RFS and OS. CONCLUSIONS: Stage III colon cancer located proximally carried a poorer survival than that located distally. Different efficacies of FOLFOX adjuvant chemotherapy may be an important factor affecting survival of site-specific stage III colon cancers.


Subject(s)
Adenocarcinoma/secondary , Adenocarcinoma/therapy , Colonic Neoplasms/pathology , Colonic Neoplasms/therapy , Adenocarcinoma/chemistry , Adenocarcinoma/mortality , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cecal Neoplasms/chemistry , Cecal Neoplasms/pathology , Cecal Neoplasms/therapy , Chemotherapy, Adjuvant , Colon/pathology , Colonic Neoplasms/chemistry , Colonic Neoplasms/mortality , DNA-Binding Proteins/analysis , Disease-Free Survival , Endonucleases/analysis , Female , Fluorouracil/administration & dosage , Humans , Leucovorin/administration & dosage , Liver Neoplasms/secondary , Lung Neoplasms/secondary , Male , Middle Aged , Neoplasm Grading , Neoplasm Staging , Organoplatinum Compounds/administration & dosage , Retrospective Studies , Survival Rate , Thymidylate Synthase/analysis
5.
Gan To Kagaku Ryoho ; 42(10): 1211-4, 2015 Oct.
Article in Japanese | MEDLINE | ID: mdl-26489551

ABSTRACT

A 65-year-old woman underwent iliocecal resection for cecal cancer. During post-operative follow-up, she was diagnosed with metastasis to the abdominal wall and a curative resection was performed. After 12 courses of adjuvant chemotherapy with a modified combination of folinic acid, 5-fluorouracil, and oxaliplatin (mFOLFOX6), recurrence was noted in the lung. A curative resection was successfully performed and she was subsequently treated with bevacizumab and a combination of folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI). One year after surgical resection, recurrence in the remnant lung was diagnosed. Because of the KRAS mutation, she could not be treated with anti-epidermal growth factor antibodies. The metastatic lung tumor continued to enlarge. Therefore, we selected regorafenib as third-line chemotherapy. After treatment with regorafenib, the size of the target lesion decreased significantly.


Subject(s)
Cecal Neoplasms/genetics , Cecal Neoplasms/pathology , Lung Neoplasms/drug therapy , Phenylurea Compounds/therapeutic use , Proto-Oncogene Proteins/genetics , Pyridines/therapeutic use , ras Proteins/genetics , Aged , Cecal Neoplasms/therapy , Female , Humans , Lung Neoplasms/secondary , Mutation , Proto-Oncogene Proteins p21(ras) , Recurrence , Time Factors , Tomography, X-Ray Computed
6.
Pol Merkur Lekarski ; 38(223): 32-3, 2015 Jan.
Article in Polish | MEDLINE | ID: mdl-25763585

ABSTRACT

Acute appendicitis can be the first symptom of the malignant tumour of the cecum. In the article we described case of 76 years old patient who came to the hospital on account pain in the right iliac hole, occurrent for 4 days with nausea and vomiting. Primarily patient classified to the appendectomy. The ultrasound examination showed the pathological mass in projection ileocecal valve and appendicitis. The computer tomography of the abdomen confirmed this diagnosis. The patient became classified to the right-sides hemicolectomy. The result of histopathological examination is adenocarcinoma of the ileocaecal valve and the appendicitis phlegmonous. Patient became classified to the adiuvant chemotherapy in the regional oncological centre.


Subject(s)
Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Appendicitis/diagnosis , Cecal Neoplasms/diagnosis , Cecal Neoplasms/pathology , Adenocarcinoma/complications , Adenocarcinoma/therapy , Aged , Appendicitis/complications , Appendicitis/pathology , Cecal Neoplasms/complications , Cecal Neoplasms/therapy , Diagnosis, Differential , Humans , Male , Tomography, X-Ray Computed
8.
World J Surg Oncol ; 12: 107, 2014 Apr 23.
Article in English | MEDLINE | ID: mdl-24755405

ABSTRACT

There are few reported cases of colorectal metastasis from cancers of other organs, particularly other segments of the colon. Here we describe the long-term survival of a 68-year-old male patient with metachronous rectal metastasis from cecal cancer who underwent repetitive resection and chemotherapy. The patient underwent ileocecal resection and hepatectomy for cecal cancer with liver metastasis (T3, N1a, M1a, Stage IVA) in 2006. The patient subsequently underwent splenectomy for splenic metastasis in 2007. In August 2008, barium enema revealed compression of the rectal wall, and abdominal computed tomography (CT) detected a mass along the rectum extending into the pelvis. Rectal metastasis from cecal cancer was suspected and Hartmann's operation with bilateral seminal vesicle dissection was performed. Histological examination of the excised tumor revealed moderately differentiated adenocarcinoma formed in the muscularis propria of the rectum and infiltrating the connective tissue between the seminal vesicle and rectum. However, no tumor was detected in the rectal mucosa or submucosa. These histological findings supported the diagnosis of rectal metastasis from cecal cancer. The patient has been monitored at our clinic for 60 months after surgical removal of the rectal metastasis. The findings from this case should alert oncologists to the potential danger of rectal metastasis from primary colon cancer and the benefits of timely complete resection in terms of improved patient outcomes.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cecal Neoplasms/mortality , Hepatectomy/mortality , Liver Neoplasms/mortality , Neoplasms, Second Primary/mortality , Rectal Neoplasms/mortality , Splenic Neoplasms/mortality , Adenocarcinoma/mortality , Adenocarcinoma/secondary , Adenocarcinoma/therapy , Aged , Cecal Neoplasms/pathology , Cecal Neoplasms/therapy , Combined Modality Therapy , Humans , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Male , Neoplasms, Second Primary/secondary , Neoplasms, Second Primary/therapy , Prognosis , Rectal Neoplasms/secondary , Rectal Neoplasms/therapy , Splenic Neoplasms/secondary , Splenic Neoplasms/therapy , Survival Rate , Tomography, X-Ray Computed
9.
J Pak Med Assoc ; 63(1): 148-9, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23865157

ABSTRACT

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract, histological and immunohistochemistry findings help to differentiate such tumours from other gastrointestinal malignancies. Metastasis is common to the stomach and small bowel and often presents with gastrointestinal bleeding. This is a case of an 82 year old man with an inguinal mass that following exploratory examination was found on histology to be a GIST metastases, imaging also showed pulmonary metastases. Following colonoscopy the primary caecal mass was found. Such metastatic presentations are extremely rare for this type of tumour. This case report highlights these unusual findings.


Subject(s)
Abdominal Neoplasms/secondary , Cecal Neoplasms/pathology , Gastrointestinal Stromal Tumors/secondary , Inguinal Canal , Lung Neoplasms/secondary , Abdominal Neoplasms/diagnosis , Abdominal Neoplasms/therapy , Aged, 80 and over , Cecal Neoplasms/therapy , Gastrointestinal Stromal Tumors/diagnosis , Gastrointestinal Stromal Tumors/therapy , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Male
11.
J Clin Gastroenterol ; 46(6): 509-14, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22105183

ABSTRACT

BACKGROUND AND GOALS: Non-Hodgkin's lymphoma (NHL) involving the ileocecal region is a rare occurrence. Optimal management and treatment outcomes of ileocecal NHL have not been well defined. STUDY: In this study, clinical characteristics, treatment outcomes, and prognostic factors of 46 Chinese patients with ileocecal NHL were retrospectively analyzed. RESULTS: Among 46 patients, the median age of these patients was 46 years and 84.8% of them were male. Twenty-four cases (52.2%) had early-stage disease (stage I/II1/II2) and 35 (76.1%) cases were of B-cell origin. Higher incidence of fever (P=0.001) and intestinal perforation (P=0.038) at onset was observed in T-cell lymphomas. Surgical emergencies occurred in 13 patients, including 8 patients who were receiving chemotherapy. Patients with T-cell advanced ileocecal NHL (stage IIE/IV) suffered more surgical emergencies during chemotherapy than others (P=0.005). The 5-year overall survival and progression-free survival rates for these 46 patients were 64.2% and 49.3%, respectively. Early-stage cases undergoing radical resection before chemotherapy had a prolonged 5-year progression-free survival rate (P=0.01). In multivariate analysis, both advanced stage and T-cell phenotype were identified as independent prognostic factors for poor survival. CONCLUSIONS: Radical resection before chemotherapy should be considered in early-stage ileocecal NHL to achieve a better survival. Palliative resection of the primary lesion before chemotherapy may be necessary in T-cell advanced cases to avoid surgical emergencies during chemotherapy. Owing to the small sample number in this study, a prospective analysis with larger sample number is highly necessary.


Subject(s)
Cecal Neoplasms/therapy , Ileal Neoplasms/therapy , Lymphoma, Non-Hodgkin/therapy , Adult , Aged , Antineoplastic Agents/therapeutic use , Cecal Neoplasms/diagnosis , Cecal Neoplasms/pathology , China , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Ileal Neoplasms/diagnosis , Ileal Neoplasms/pathology , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Multivariate Analysis , Neoplasm Staging , Prognosis , Retrospective Studies , Survival Rate , Treatment Outcome , Young Adult
12.
Surg Today ; 40(10): 975-81, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20872204

ABSTRACT

This report presents the case of a 62-year-old man with a collision tumor of primary malignant lymphoma and adenocarcinoma in the cecum. All regional mesenteric lymph nodes that were removed surgically were found to be occupied by lymphoma cells and no lymph nodes contained any cancer cells, although the primary carcinomas did exhibit lymphatic invasion. Malignant lymphoma was also seen in the duodenum. Systemic chemotherapy was administered for the malignant lymphoma, and a complete response was thus obtained. However, just after chemotherapy multiple liver metastases of adenocarcinoma emerged, and chemotherapy against adenocarcinoma was therefore continued. The occurrence of synchronous lymphoma and adenocarcinoma of the colorectum is rare. Furthermore, collisions of these different entities are also extremely unusual; so far only five such case reports have been published. The accurate clinical determination of the dominant tumor and a close follow-up is required for proper treatment in these cases.


Subject(s)
Adenocarcinoma/diagnosis , Cecal Neoplasms/diagnosis , Duodenal Neoplasms/diagnosis , Lymphoma, B-Cell/diagnosis , Lymphoma, Follicular/diagnosis , Neoplasms, Multiple Primary/diagnosis , Adenocarcinoma/therapy , Antineoplastic Agents/therapeutic use , Biopsy, Needle , Cecal Neoplasms/therapy , Colectomy/methods , Colonoscopy , Duodenal Neoplasms/therapy , Humans , Lymphoma, B-Cell/therapy , Lymphoma, Follicular/surgery , Male , Middle Aged , Neoplasm Staging , Neoplasms, Multiple Primary/therapy , Tomography, X-Ray Computed
13.
Cancer Med ; 9(16): 5851-5859, 2020 08.
Article in English | MEDLINE | ID: mdl-32614506

ABSTRACT

Primary tumor location is an established prognostic factor in patients with (metastatic) colon cancer. Colon tumors can be divided into left-sided and right-sided tumors. The aim of this study was to determine the impact of primary tumor location on treatment and overall survival (OS) in patients with peritoneal metastases (PM) from colon cancer. This study is a retrospective, population-based cohort study. Records of patients diagnosed with colon cancer and synchronous PM, from 1995 through 2016, were retrieved from the Netherlands Cancer Registry (NCR). Data on diagnosis, staging, and treatment were extracted from the medical records by specifically trained NCR personnel. Information on survival status was updated annually using a computerized link with the national civil registry. In total, 7930 patients were included in this study; 4555 (57.4%) had a right-sided and 3375 (42.6%) had a left-sided primary tumor. In multivariable analysis right-sided primary tumor was associated with worse OS (HR: 1.11, 95% CI 1.03-1.19, P = .007). Of all patients diagnosed with PM, 564 (7.1%) underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Patients with left-sided primary tumors were more often candidates for CRS-HIPEC (6.5% vs. 8.0%, P = .008). OS of patients with right- and left-sided tumors who underwent CRS-HIPEC did not significantly differ. In conclusion, primary right-sided colon cancer was an independent prognostic factor for decreased OS in patients diagnosed with synchronous PM. In patients treated with CRS-HIPEC location of the primary tumor did not influence survival.


Subject(s)
Colonic Neoplasms/pathology , Peritoneal Neoplasms/secondary , Aged , Cecal Neoplasms/mortality , Cecal Neoplasms/pathology , Cecal Neoplasms/therapy , Colon, Ascending , Colon, Descending , Colon, Transverse , Colonic Neoplasms/mortality , Colonic Neoplasms/therapy , Cytoreduction Surgical Procedures , Female , Humans , Hyperthermic Intraperitoneal Chemotherapy/mortality , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Netherlands , Palliative Care , Peritoneal Neoplasms/mortality , Peritoneal Neoplasms/therapy , Prognosis , Retrospective Studies , Sigmoid Neoplasms/mortality , Sigmoid Neoplasms/pathology , Sigmoid Neoplasms/therapy , Survival Analysis
14.
Oncology (Williston Park) ; 23(8): 683-90, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19711582

ABSTRACT

Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma that remains incurable, and is associated with a median survival of approximately 5 years. Management of patients with relapsed or refractory disease is challenging. The major therapeutic goal in MCL management is to improve survival and quality of life whenever possible. Progress has been made in MCL therapy in the past decade based on clinical experimentation with novel agents and combinations. There is a growing list of conventional and novel agents in our armamentarium, consisting of not only additional chemotherapy combinations including high-dose approaches, but also biologically targeted reagents such as the monoclonal antibody rituximab, the proteasome inhibitor bortezomib, the mTOR inhibitor temsirolimus, immunomodulatory and antiangiogenic agents including thalidomide and lenalidomide, and cyclin-dependent kinase inhibitors, as well as a renewed interest in older compounds such as bendamustine and metronomic regimens. Efficacy evaluations for individual agents and rational combinations are in various stages of development, while treatment selection based on molecular and clinical prognostic scores is yet to be tested. In the absence of evidence demonstrating relative survival advantages of various second-line options, management of relapsed and refractory disease should be individualized. Involvement of a lymphoma center participating in clinical trials of novel MCL treatments is encouraged.


Subject(s)
Cecal Neoplasms/therapy , Lymphoma, Mantle-Cell/therapy , Neoplasm Recurrence, Local/therapy , Aged , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Humans , Male
15.
Gan To Kagaku Ryoho ; 36(12): 2070-2, 2009 Nov.
Article in Japanese | MEDLINE | ID: mdl-20037326

ABSTRACT

A 33-year-old man, who underwent ileo-cecal resection and sigmoidectomy for concomitant cecal cancer and sigmoid colon cancer which was diagnosed during the emergent operation for the perforated acute appendicitis, suffered simultaneous multiple hepatic metastases. Postoperative hepatic aerial infusion chemotherapy with 5-FU was done (total dose 63 g), and the metastases were successfully disappeared (CR). Although 16-month passed from the operation, locoregional recurrence at the colorectal anastomosis and peritoneal dissemination were occurred. Aggressive resections of the recurrent sites (anterior resection of the rectum, ileum, ascending colon and other recurrent sites) and successive systemic administration of FOLFOX4(9-course), FOLFIRI (20-course) and capecitabine (15-course) were achieved. The patient survived for 4.5 years after the initial treatment.


Subject(s)
Cecal Neoplasms/pathology , Cecal Neoplasms/therapy , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Sigmoid Neoplasms/pathology , Sigmoid Neoplasms/therapy , Adult , Combined Modality Therapy , Humans , Male
16.
N Engl J Med ; 362(25): 2411-9, 2010 Jun 24.
Article in English | MEDLINE | ID: mdl-20573930
18.
Oncol Rep ; 18(4): 763-7, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17786333

ABSTRACT

Malignant triton tumor (MTT) is a rare, highly malignant nerve sheath tumor with rhabdomyoblastic differentiation. Initial debulking surgery followed by adjuvant therapy is the current treatment of choice, but has very limited efficacy when optimal cytoreduction is not achieved by surgical procedure. Neoadjuvant therapy for MTT, to potentially facilitate subsequent surgery, eradicate micrometastatic lesions and, therefore, improve the therapeutical outcome, has never before been presented in literature. Here, we report on the multimodal management of two cases of advanced and metastatic MTT. Treatment modalities involved neoadjuvant and adjuvant chemotherapy, surgical resection, and radiation. In both cases, integrated Positron Emission Tomography/Computed Tomography (PET/CT) emerged as an important diagnostic tool for the reliable assessment of MTT response and metabolic remission.


Subject(s)
Cecal Neoplasms/therapy , Ileal Neoplasms/therapy , Liver Neoplasms/therapy , Neurilemmoma/therapy , Ovarian Neoplasms/drug therapy , Uterine Neoplasms/therapy , Adult , Antineoplastic Agents/therapeutic use , Cecal Neoplasms/drug therapy , Cecal Neoplasms/radiotherapy , Cecal Neoplasms/surgery , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Fluorodeoxyglucose F18 , Humans , Ileal Neoplasms/drug therapy , Ileal Neoplasms/radiotherapy , Ileal Neoplasms/surgery , Liver Neoplasms/drug therapy , Liver Neoplasms/radiotherapy , Liver Neoplasms/surgery , Male , Neoadjuvant Therapy , Neurilemmoma/drug therapy , Neurilemmoma/radiotherapy , Neurilemmoma/surgery , Neurofibromatosis 1/pathology , Ovarian Neoplasms/pathology , Positron-Emission Tomography , Radiopharmaceuticals , Tomography, X-Ray Computed , Uterine Neoplasms/drug therapy , Uterine Neoplasms/radiotherapy , Uterine Neoplasms/surgery
19.
World J Surg Oncol ; 5: 2, 2007 Jan 07.
Article in English | MEDLINE | ID: mdl-17207288

ABSTRACT

BACKGROUND: Prostatic carcinoma is the second most common cause of cancer-related deaths in males in the West. Approximately 20% of patients present with metastatic disease. We describe the case of a patient with metastatic prostate cancer to the bowel presenting clinically and radiologically as a primary caecal cancer. CASE PRESENTATION: A 72 year-old man presented with abdominal discomfort and a clinically palpable caecal mass and a firm nodule on his thigh, the latter behaving clinically and radiologically as a lipoma. Computed tomographic (CT) scan showed a luminally protuberant caecal mass with regional nodal involvement. The patient was being treated (Zoladex) for prostatic cancer diagnosed 6 years previously and was known to have bony metastases. On admission his PSA was 245.4 nmol/ml. The patient underwent a right hemicolectomy. Histology showed a poorly differentiated adenocarcinoma which was PSA positive, confirming metastatic prostatic adenocarcinoma to the caecum. The patient underwent adjuvant chemotherapy and is free from recurrence a year later. CONCLUSION: Metastasis of prostatic carcinoma to the bowel is a very rare occurrence and presents a challenging diagnosis. The diagnosis is supported by immunohistochemistry for PSA. The treatment for metastatic prostate cancer is mainly palliative.


Subject(s)
Adenocarcinoma/secondary , Cecal Neoplasms/secondary , Cecal Neoplasms/therapy , Prostatic Neoplasms/pathology , Adenocarcinoma/complications , Adenocarcinoma/diagnosis , Adenocarcinoma/therapy , Aged , Biopsy, Needle , Cecal Neoplasms/complications , Cecal Neoplasms/diagnosis , Chemotherapy, Adjuvant , Colectomy/methods , Diagnosis, Differential , Follow-Up Studies , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/etiology , Humans , Immunohistochemistry , Male , Neoplasm Staging , Prostatectomy/methods , Prostatic Neoplasms/complications , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/therapy , Rectum , Risk Assessment , Tomography, X-Ray Computed , Treatment Outcome
20.
Auris Nasus Larynx ; 33(1): 85-8, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16169179

ABSTRACT

Metastatic carcinoma of the palatine tonsil is unusual. The most common primary sites of the tonsillar metastasis are the kidney, cutaneous melanoma, lung and breast. Primary manifestation of these tumors as a tonsillar mass is extremely rare in the literature. We present a case with a tonsillar metastasis from unusually localized primary signet ring-cell carcinoma of the cecum.


Subject(s)
Carcinoma, Signet Ring Cell/pathology , Carcinoma, Signet Ring Cell/secondary , Cecal Neoplasms/pathology , Tonsillar Neoplasms/secondary , Adult , Carcinoma, Signet Ring Cell/therapy , Cecal Neoplasms/therapy , Humans , Male , Tonsillar Neoplasms/diagnosis , Tonsillar Neoplasms/therapy
SELECTION OF CITATIONS
SEARCH DETAIL